World First: Gene Therapy Aims to Rejuvenate Eye Cells

A single injection, a harmless virus and a pill that flips a genetic switch — that is the bold bet now playing out in a small clinic. Life Biosciences announced this week that it has dosed the first patient with ER-100, an experimental gene therapy designed to restore retinal ganglion cells to a younger, more functional state.

Retinal ganglion cells are the cable lines between the eye and the brain. They do not regrow once damaged. Diseases like open-angle glaucoma and ischemic optic neuropathy can destroy these neurons quietly and irreversibly, stealing vision without fanfare. ER-100 attempts to change that by turning on three genes inside those very cells.

The delivery system is a virus stripped of its ability to cause infection; it acts as a courier for genetic instructions. Those instructions prompt the cells to produce proteins linked with a younger cellular identity. Control is built in: the introduced genes are governed by a switch that only flips on when participants take a specific antibiotic. Stop the pill, and the switch clicks off. Simple in concept. Risky in practice.

This is a first-in-human trial approved by regulators earlier this year. It will enroll up to 18 people, beginning with 12 participants who have open-angle glaucoma and later including up to six with nonarteritic anterior ischemic optic neuropathy. Patients will be dosed one at a time in a cautious, dose-escalation design and monitored for at least five years for safety and any signs of visual improvement.

The idea behind ER-100 comes from work at Harvard showing that partial cellular reprogramming can make aged cells behave more like younger ones. David Sinclair, a co-founder of Life Biosciences and a prominent figure in aging research, has framed aging as a loss of epigenetic information — molecular annotations that tell DNA how to behave. If those markings can be reset, he and others argue, some age-related decline might be reversible.

Laboratory results, including studies in mice and non-human primates, gave the developers reason for optimism. But human biology is different. Manipulating gene expression is a double-edged sword. Changing cellular identity could restore function. It could also produce unanticipated effects, including abnormal growth or cancer. Short-term gains could fade if the underlying drivers of a disease — for example, the raised eye pressure in glaucoma — are not addressed.

Not everyone is convinced the timing is right. Some scientists call the approach 'extraordinarily high-risk' and warn that enthusiasm can outpace evidence. Others welcome the experiment as the clearest test yet of whether epigenetic reprogramming can translate from mice to people. Either way, the trial is deliberately small and safety-focused — it is not a broad statement that aging can be turned back across the body.

Beyond the immediate safety questions, the study highlights a deeper scientific debate: what does 'reversing aging' actually mean? Researchers measure biological age with a variety of molecular clocks, and it remains unclear which clocks matter most for tissue function — or whether they must all be reset to declare genuine rejuvenation.

Results from this trial will be modest at first: proof that the therapy can be delivered safely and hints about vision changes. But modest beginnings can lead to outsized consequences. Is this the start of a new class of regenerative therapies? Or an experiment whose risks outweigh its promise? The first human data will tell us which story is closer to the truth.